CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intest Res. 2021;19(4):386-397.   Published online December 1, 2020
DOI: https://doi.org/10.5217/ir.2020.00080

Excel Download

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intestinal Research. 2021;19(4):386-397   Crossref logo
Link1 Link2 Link3
Efficacy and safety of ustekinumab in Russian bionaive patients with moderately to severely active ulcerative colitis: a subanalys is of global phase 3 induction and maintenance studies (UNIFI) up to 3 years
E. A. Belousova, R. A. Abdulkhakov, I. G. Bakulin, A. V. Kulyapin, A. V. Tkachev, Colleen Marano, Ye Miao
Koloproktologia. 2023;22(1):54-64   Crossref logo
Link1
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink
Intestinal Research. 2017;15(4):475   Crossref logo
Link1 Link2 Link3
Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Marla C. Dubinsky, Keith Betts, Devrim Eren, Wenxi Tang, Lei Yin, Komal Gupte-Singh
Gastroenterology. 2022;162(7):S-602   Crossref logo
Link1 Link2
P519 Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
S Friedrich, L Chua, X C Zhang
Journal of Crohn's and Colitis. 2023;17(Supplement_1):i646-i646   Crossref logo
Link1 Link2
P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
W Reinisch, R Panaccione, M Duijvestein, D Ceballos Santos, G Y Melmed, S Xuan, L Wegrzyn, G Levy, D Ilo, Y Sanchez Gonzalez
Journal of Crohn's and Colitis. 2023;17(Supplement_1):i672-i673   Crossref logo
Link1 Link2
P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies
S Danese, B E Sands, R W Leong, H Zhang, J Johanns, P Szapary, C Marano, C Han
Journal of Crohn's and Colitis. 2019;13(Supplement_1):S311-S312   Crossref logo
Link1
OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
R Panaccione, E B Collins, G Y Melmed, S Vermeire, S Danese, P D R Higgins, W Zhou, D Ilo, D Sharma, Y Sanchez Gonzalez, S T Wang
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i037-i041   Crossref logo
Link1 Link2
OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
G D’Haens, T Kobayashi, N Morris, T Lissoos, A Hoover, X Li, V Arora, C Milch, W J Sandborn, B E Sands
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i028-i029   Crossref logo
Link1 Link2
Sa1887 – General Health Status in Patients with Moderate to Severe Ulcerative Colitis Receiving Ustekinumab: Results from the Phase 3 Unifi Induction and Maintenance Studies
Silvio Danese, Bruce E. Sands, Rupert W. Leong, Hongyan Zhang, Jewel Johanns, Philippe Szapary, Colleen W. Marano, Chenglong Han
Gastroenterology. 2019;156(6):S-442   Crossref logo
Link1 Link2